Bios Partners is a venture capital firm focused on investing in early-stage biopharmaceutical and medical device companies. Founded in 2014 and based in Fort Worth, TX, the firm utilizes an experienced team of industry professionals to actively collaborate with its investment portfolio companies and enhance stakeholder value.
Hatteras Venture Partners
Hatteras Venture Partners is a venture capital firm based in Durham, N.C. with a focus on seed and early stage opportunities across the health care continuum from transformational therapies to disruptive technologies. The firm has over $550 milion in capital commitments under management.
Access Biotechnology is the life science investment arm of Access Industries. The investment strategy is broad, long term and aims to enable truly innovative therapeutic platforms and products across three key stages: company foundation, technology translation and company expansion. Our approach is based on rigorous diligence and we provide value-added support from our extensive experience and networks.
AJU IB Investment Company
AJU Life Sciences Overseas Expansion Platform Fund is part of AJU IB Investment Co., Ltd., a leading venture capital firm headquartered in Seoul Korea with approximately USD $1 billion in capital under management. AJU IB Investment’s US office invests exclusively in companies developing pioneering new therapies or medical technologies.
Correlation Ventures leverages world-class analytics to offer entrepreneurs and other venture capitalists a dramatically better option when they are seeking additional co-investment capital to complete a financing round.
ExSight is a venture capital firm specializing in early-stage impact investments in innovative ophthalmic diagnostic and treatment solutions. The firm seeks investments in biotechnology, medical devices, pharmaceuticals and software solutions in ophthalmology.
InFocus Capital Partners
InFocus Capital Partners provides seed and early round funding to life science companies, specifically within ophthalmology. Their strategy has focused on identifying start-up opportunities with disruptive potential, seasoned management and attractive valuation.